Improved 24-Hour Migraine Quality of Life with Rizatriptan 10 mg compared to Non-Triptan Treatment. I-MAX Migraine Disability Assessment Program, Spain

By Gerth W.C.   Bertral C.   Ester F.   Castellanos A.   Caloto M.T.   Nocea G.  

Headache Care, Vol. 1, Iss. 1, 2004-03 ,pp. : 46-49

Informa Healthcare

Access to resources Recommend Favorite

Usefulness of a Disability Diary to Facilitate Communication Between Migraine Patients and Primary Care Physicians in Assessing Symptoms, Migraine-related Disability and Medication Effectiveness. The I-MAX Migraine Disability Assessment Program, Spain

By Baos V.   Torrecilla M.   Serrano A.   Caloto M.T.   Nocea G.   Gerth W.C.  

Headache Care, Vol. 1, Iss. 1, 2004-03 ,pp. : 33-38

Informa Healthcare

Access to resources Recommend Favorite

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine

By Dahlöf Carl   Jones Martin   Davis Kim   Loftus Jane   Salonen Reijo  

The Journal of Headache and Pain, Vol. 5, Iss. 2, 2004-08 ,pp. : 115-122

Springer Publishing Company

Access to resources Recommend Favorite

Optimising Treatment for Migraine Patients Using the ZAP Migraine Treatment Algorithm and Triptan Formulation Finder

By Almqvist Per  

Headache Care, Vol. 2, Iss. 4, 2005-12 ,pp. : 251-255

Informa Healthcare

Access to resources Recommend Favorite

Patient preference in migraine therapy: A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan

By Díez Fernando   Straube Andreas   Zanchin Giorgio  

Journal of Neurology, Vol. 254, Iss. 2, 2007-02 ,pp. : 242-249

Springer Publishing Company

Access to resources Recommend Favorite